311 drugs not selected for centralized purchase and 165 drugs with price reduction suspended

On January 15, Anhui Province issued the document "notice on carrying out the linkage price reduction work of drugs related to the centralized drug procurement varieties in the alliance region (Anhui Province)", 311 varieties will apply for price reduction independently, and those who fail to apply for price reduction according to the regulations will be disqualified from the network According to the notice of the general office of the State Council on printing and distributing the pilot program of centralized purchase and use of drugs organized by the state, the implementation opinions of nine departments such as the State Medical Insurance Bureau on expanding the regional scope of the pilot program of centralized purchase and use of drugs organized by the state and the implementation plan of Anhui Province on expanding the scope of the pilot program of centralized purchase and use of drugs organized by the state, the notice is clear: Among the 25 varieties, the original research drug and reference drug that need to declare the price reduction independently and the generic drug that has passed the consistency evaluation of national quality and efficacy involve 191 product specifications In addition, the other generic drugs that need to declare the price reduction independently involve 120 product specifications, a total of 311 drugs For the follow-up newly added drugs, if they belong to the 25 drugs involved in the list of selected varieties of centralized drug procurement in the alliance region, if they apply for online procurement, they shall apply for price reduction by referring to this notice The document shows that if the drug is not selected, it is necessary to implement gradient price reduction according to the price difference on the basis of the current online purchase price If the price difference is large, the price reduction range should be further increased Among them, the original research drug, reference preparation, and generic drugs that have passed the consistency evaluation of national quality and efficacy shall be independently declared by the drug manufacturer as the lowest supply price in the country within the specified time limit If Anhui Province is not selected as the supply area, the independent price reduction shall not be higher than the lowest supply price of other non selected supply areas in the country Other generic drugs can be purchased online only when their prices are lower than those of the same varieties in the centralized purchase of drugs in the alliance region (Anhui Province) The drug manufacturer shall, within the prescribed time limit, independently declare the price reduction (if the dosage form, specification and package have a difference ratio relationship, it shall be calculated according to the difference ratio rule) The document also provides penalties for pharmaceutical companies: The relevant pharmaceutical manufacturers shall strictly abide by the principle of honesty and trustworthiness, ensure the authenticity and accuracy of the declaration items, and include the complained and reported enterprises in the list of enterprises with bad records of commercial bribery in the field of pharmaceutical purchase and sale in Anhui province if verified; If the price reduction is not declared independently within the prescribed time limit, the online purchasing qualification of the product in Anhui Province will be cancelled, and relevant enterprises can apply for resuming online purchasing after declaring and meeting the standard; There is no need to declare the drugs that meet the relevant requirements in the current online purchase price of provincial pharmaceutical centralized purchase platform Encourage the products of different specifications with the same generic name to apply for independent price reduction Coincidentally, on the same day of the 15th, Anhui Province issued a notice that a batch of 4 + 7 unsuccessful drugs had been stopped from purchasing According to the requirements of documents such as the implementation plan of Anhui Province for the implementation of the pilot expansion of centralized procurement and use of drugs organized by the state, sebilan has learned that if there are more than three manufacturers that have passed the consistency evaluation of the same type of drugs selected, under the condition of ensuring supply, the varieties that have not passed the consistency evaluation will not be used in the centralized procurement of drugs, and now some of them have not passed the imitation Evaluation of the consistency of drug quality and efficacy If the drugs of related enterprises pass the consistency evaluation of quality and efficacy of generic drugs, they can submit relevant supporting materials and apply for resumption of online procurement From the above two documents, on the one hand, Anhui province requires 311 non selected drugs of centralized purchase to reduce the price, and at the same time, 165 drugs without winning the bidding of 4+7 are suspended from purchasing - the power of centralized purchase appears in front of us in the most intuitive way According to the data of Fengyun Pharma, the market share of the original research products has declined in the whole line under the national mining mechanism The data comparison between 2017 and 2019 has declined by more than 60%, and the terminal hospital market has declined significantly Compared with the decline of the selected products and the original research, the domestic competitive products of the selected products in the catalog dropped by an astonishing margin, with a decline of more than 80% in 2017-2019, including the sales data of the first quarter of 2019 It can be seen from this that under the national procurement rules, the market share of unselected products and non evaluated products in clinical terminals will be severely impacted, among which the two documents of Anhui Province are the epitome From August 2018 to now, the market has digested negative expectations on volume procurement for nearly a year, while after the second half of 2019, "4 + 7" gradually linked to the whole country Under this trend, the change of "volume" pattern of bidding and procurement will be eased, which will promote the structural change brought by the acceleration of consistency evaluation varieties in the short term, while in the long term, it will reshape the overall pattern of the pharmaceutical industry, and R & D will determine the future trend Already.